Partner Kim Ashby was recently profiled in a Florida Super Lawyers article titled, “If You Build It… Kim Ashby Just Might Be Your Attorney.” This feature story is in conjunction with Ashby’s recognition in the 2017 Florida Super Lawyers ranking.
The article covers Ashby’s work on behalf of the Grande Lakes Resort in the Orlando area, includes quotes from individuals who work closely with her, and highlights strong aspects of her personal and professional lives. Read the full article here.
Twenty six Foley attorneys accompany Ashby in being named to the 2017 Florida Super Lawyers ranking. Click here for more information.
The article covers Ashby’s work on behalf of the Grande Lakes Resort in the Orlando area, includes quotes from individuals who work closely with her, and highlights strong aspects of her personal and professional lives. Read the full article here.
Twenty six Foley attorneys accompany Ashby in being named to the 2017 Florida Super Lawyers ranking. Click here for more information.
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”